CN116444351A - 一种核辐射损伤中对小肠有保护作用的天然小分子化合物 - Google Patents
一种核辐射损伤中对小肠有保护作用的天然小分子化合物 Download PDFInfo
- Publication number
- CN116444351A CN116444351A CN202211446781.8A CN202211446781A CN116444351A CN 116444351 A CN116444351 A CN 116444351A CN 202211446781 A CN202211446781 A CN 202211446781A CN 116444351 A CN116444351 A CN 116444351A
- Authority
- CN
- China
- Prior art keywords
- small intestine
- small
- cannabidiol
- nuclear radiation
- natural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000813 small intestine Anatomy 0.000 title claims abstract description 29
- 208000019155 Radiation injury Diseases 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 title claims abstract description 14
- 230000002633 protecting effect Effects 0.000 title abstract description 5
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 24
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 23
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 23
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 23
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 23
- 230000001681 protective effect Effects 0.000 claims abstract description 12
- 210000000130 stem cell Anatomy 0.000 claims abstract description 11
- -1 small molecule compound Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 231100000252 nontoxic Toxicity 0.000 abstract description 5
- 230000003000 nontoxic effect Effects 0.000 abstract description 5
- 231100000053 low toxicity Toxicity 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 208000037817 intestinal injury Diseases 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000218236 Cannabis Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000008697 Cannabis sativa Nutrition 0.000 description 2
- 101001120760 Homo sapiens Olfactomedin-4 Proteins 0.000 description 2
- 102100026071 Olfactomedin-4 Human genes 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010050081 Neonatal hypoxia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于医学药物技术领域,公开了一种核辐射损伤中对小肠有保护作用的天然小分子化合物,天然小分子化合物为大麻二酚;大麻二酚的单次给药剂量为50mg/kg;大麻二酚对潜在的核辐射损伤中,对小肠组织和小肠干细胞起到保护作用;本发明提供的天然小分子化合物—大麻二酚,可在潜在的核辐射损伤风险场景下,该天然小分子化合物可对小肠组织和小肠干细胞起到保护作用;而且该天然小分子化合物为植物中的无毒性成分,在有效剂量下毒性低、副作用小。
Description
技术领域
本发明涉及医学药物技术领域,具体为一种核辐射损伤中对小肠有保护作用的天然小分子化合物。
背景技术
肠道对辐射极为敏感,是造血系统之外辐射损伤的最主要的靶器官。无论是医疗照射、还是意外受照,均可能导致放射性肠损伤。辐射可导致肠道内的血管内皮细胞、粘膜上皮细胞、隐窝干细胞和肠道菌群等发生改变,主要表现为肠绒毛内血管肿胀、闭塞、破裂或减少,肠绒毛缩短、倒伏,肠壁纤维化等病理变化,临床上主要表现为以肠道炎症反应为主的食欲不振、恶心呕吐、腹痛腹泻、粘液血便等,严重者可能出现肠套叠、肠梗阻;同时,放射性肠损伤常伴有造血、免疫等多系统损伤,受照者往往死于多系统衰竭。国内外对放射性肠损伤发病机制进行了许多探索,认为电离辐射通过影响生物靶分子的结构和功能引起放射性肠损伤,主要涉及DNA损伤、蛋白质结构与修饰改变、炎症因子过度释放、信号传导失控等复杂的机理,但尚缺乏有效的放射性肠损伤防治药物。
大麻二酚(CBD)是一种天然小分子化合物,其由大麻的花叶中萃取得到,大麻二酚是大麻中的无毒、非成瘾性成分,能阻碍多酚对人体神经系统影响,并具有抗痉挛、抗焦虑等药理活性,已知可以用作治疗癫痫、糖尿病、新生儿缺氧缺血性脑病等疾病的药物的活性组分,目前主要用于药品、化妆品、保健食品等高附加值的植物提取物;而现在技术中,还没有将其用在核辐射损伤中对小肠的保护。因此,基于当前生活作业场景中存在多种的辐射风险,提出一种核辐射损伤中对小肠有保护作用的天然小分子化合物—大麻二酚。
发明内容
本发明意在提供一种核辐射损伤中对小肠有保护作用的天然小分子化合物,可在潜在的核辐射损伤风险场景下,该天然小分子化合物可对小肠组织和小肠干细胞起到保护作用;而且该天然小分子化合物为植物中的无毒性成分,在有效剂量下毒性低、副作用小。
为了实现上述目的,本发明提供如下技术方案:
一种核辐射损伤中对小肠有保护作用的天然小分子化合物,所述天然小分子化合物为大麻二酚。
进一步地,所述大麻二酚的单次给药剂量为50mg/kg。
进一步地,所述大麻二酚对潜在的核辐射损伤中,对小肠组织和小肠干细胞起到保护作用。
技术方案的有益效果是:
大麻二酚为大麻中的无毒性成分,在有效剂量下具有毒性低、副作用小的优点;将其应用在潜在的核辐射损伤风险场景下,对小肠组织和小肠干细胞起到保护作用。
附图说明
图1为实验小鼠经8.5Gy照射后是否给药的小肠绒毛长度对比图;
图2为实验小鼠经8.5Gy照射后是否给药的第三天对OLFM4的染色显示对比图;
图中,代号CB2022对应的为注射大麻二酚实验组。
具体实施方式
下面结合附图和实施方式对本发明作进一步的详细说明:
材料和方法
1.1动物选择
C57BL/6J小鼠,日龄50天左右,体重18~22g,每组10只,均为雄鼠。
1.2药物配制
大麻二酚由军事医学研究院提供。实验前,将大麻二酚溶于大豆油中,浓度为5mg/ml,用前现配,一次使用,实验选择的给药剂量为50mg/kg,腹腔注射给药。
1.3照射条件
小鼠照射在军事医学研究院进行,采用钴-60源。吸收剂量为8.5Gy。
1.4量效实验
在辐照前12小时、0.5小时和辐照后12小时、24小时共四次腹腔注射给药;,单次给药剂量为50mg/kg。
实验结果:如图1所示,8.5Gy照射后第三天,与正常组织相比,照射组小鼠的小肠绒毛长度明显缩短,内容物减少,而CB2022给药组绒毛长度未见明显缩短,且至30天时仍无明显损伤。
如图2所示,辐照后第三天对OLFM4的染色显示照射小鼠的小肠中小肠干细胞数量与正常组织相比大幅减少,CB2022组仅出现少量隐窝内有小肠干细胞减少,整体数量水平接近正常组织,说明CB2022对照射后小肠干细胞具有保护作用。
基于上述实验可知,可在潜在的核辐射风险场景下,通过肌肉注射等方式使用该天然小分子化合物—大麻二酚,大麻二酚的单次给药剂量为50mg/kg,对小肠组织和小肠干细胞起到保护作用;而且大麻二酚为大麻中的无毒性成分,在有效剂量下具有毒性低、副作用小。
以上所述的仅是本发明的实施例,方案中公知的具体技术方案或特性等常识在此未作过多描述。应当指出,对于本领域的技术人员来说,在不脱离本发明技术方案的前提下,还可以作出若干变形和改进,这些也应该视为本发明的保护范围,这些都不会影响本发明实施的效果和专利的实用性。本申请要求的保护范围应当以其权利要求的内容为准,说明书中的具体实施方式等记载可以用于解释权利要求的内容。
Claims (3)
1.一种核辐射损伤中对小肠有保护作用的天然小分子化合物,其特征在于,所述天然小分子化合物为大麻二酚。
2.根据权利要求1所述的一种核辐射损伤中对小肠有保护作用的天然小分子化合物,其特征在于:所述大麻二酚的单次给药剂量为50mg/kg。
3.根据权利要求1所述的一种核辐射损伤中对小肠有保护作用的天然小分子化合物,其特征在于:所述大麻二酚对潜在的核辐射损伤中,对小肠组织和小肠干细胞起到保护作用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211446781.8A CN116444351A (zh) | 2022-11-18 | 2022-11-18 | 一种核辐射损伤中对小肠有保护作用的天然小分子化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211446781.8A CN116444351A (zh) | 2022-11-18 | 2022-11-18 | 一种核辐射损伤中对小肠有保护作用的天然小分子化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116444351A true CN116444351A (zh) | 2023-07-18 |
Family
ID=87130865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211446781.8A Pending CN116444351A (zh) | 2022-11-18 | 2022-11-18 | 一种核辐射损伤中对小肠有保护作用的天然小分子化合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116444351A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106692201A (zh) * | 2016-12-30 | 2017-05-24 | 江阴市本特塞缪森生命科学研究院有限公司 | 一种防治放射性口腔粘膜炎的组合物及其应用 |
WO2017204986A1 (en) * | 2016-05-27 | 2017-11-30 | Insys Development Company, Inc. | Stable cannabinoid formulations |
WO2018200024A1 (en) * | 2017-04-27 | 2018-11-01 | Insys Development Company, Inc. | Stable cannabinoid formulations |
CN113679700A (zh) * | 2020-05-19 | 2021-11-23 | 四川大学华西医院 | 大麻二酚在保护皮肤免受紫外线诱导的dna损伤中的应用 |
-
2022
- 2022-11-18 CN CN202211446781.8A patent/CN116444351A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017204986A1 (en) * | 2016-05-27 | 2017-11-30 | Insys Development Company, Inc. | Stable cannabinoid formulations |
CN106692201A (zh) * | 2016-12-30 | 2017-05-24 | 江阴市本特塞缪森生命科学研究院有限公司 | 一种防治放射性口腔粘膜炎的组合物及其应用 |
WO2018200024A1 (en) * | 2017-04-27 | 2018-11-01 | Insys Development Company, Inc. | Stable cannabinoid formulations |
CN113679700A (zh) * | 2020-05-19 | 2021-11-23 | 四川大学华西医院 | 大麻二酚在保护皮肤免受紫外线诱导的dna损伤中的应用 |
Non-Patent Citations (1)
Title |
---|
武忠宝 等: "大麻二酚对急性放射性肺损伤保护作用及机制研究", 《临床军医杂质》, vol. 50, no. 8, pages 785 - 789 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS5823630A (ja) | 薬剤禁断症状の処置剤 | |
CN105879006A (zh) | 一种治疗糖尿病足溃疡的药物组合物及其制备方法和应用 | |
CN107106536A (zh) | 治疗伴侣动物的腹泻的方法 | |
CN116444351A (zh) | 一种核辐射损伤中对小肠有保护作用的天然小分子化合物 | |
WO2008034328A1 (fr) | Nouvelle utilisation du composé-k ginsenoside pour la fabrication de médicaments | |
CN109806246A (zh) | 丙二醇在制备用于预防肠型放射病及放射性肠炎的药物中的应用 | |
CN112569222A (zh) | 三氟淫羊藿素在制备改善疼痛、肿胀及运动功能的药物中的应用 | |
JP2599163B2 (ja) | 家畜および家禽のサルモネラ・テイフィムリウム感染症の予防及び治療剤 | |
CN101336916A (zh) | 茶多酚的用途 | |
CN101590041B (zh) | 一种镇咳的药物组合物 | |
CN114129722B (zh) | 注射用人免疫球蛋白在制备预防或治疗辐照损伤的药物中的用途 | |
CN115887426A (zh) | 大麻二酚在制备核辐射损伤后骨髓恢复药物中的应用 | |
CN102670689A (zh) | 治疗银屑病喷雾剂的制备方法 | |
US7846901B2 (en) | Method for inhibiting or treating intestinal damage caused by radiotherapy or chemotherapy comprising administering substance-P | |
CN112022865B (zh) | 白头翁皂苷b4在制备治疗糖尿病皮肤溃疡的药物中的用途 | |
CN1069210C (zh) | 一种烧烫伤液及其制备方法 | |
Griffity Jr et al. | Production of Increased Capillary Fragility in Rats Following Irradiation. | |
CN101422474A (zh) | 供静脉用异甘草酸镁制剂在治疗皮肤病中的应用 | |
CA2997112A1 (en) | Use of secoisolariciresinol diglucosides (sdgs) and related compounds for protection against radiation damage | |
Lytkin et al. | Effect of nmda-receptors antagonist on renal glucose reabsorption under the conditions of insulin resistance and chronic renal failure | |
CN114869878A (zh) | 表儿茶素没食子酸酯在制备治疗高原脑水肿药物中的应用 | |
CN104523849A (zh) | 一种杜仲环烯醚萜的药物组合物及其应用 | |
CN117695298A (zh) | 飞燕草素-3-o-葡萄糖苷在制备抗肺纤维化药品或保健品中的应用 | |
CN115177620A (zh) | 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用 | |
RU2228741C2 (ru) | Способ лечения рецидивирующего иридоциклохориоидита лошадей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |